GlassScriptPhysician profile
Holly C Brown
NPI 1851382980
$3,769.50
in general payments reported to CMS, 2019-2025
23 companies · $481 in 2025
The $481 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $666 · 2020: $207 · 2021: $657 · 2022: $509 · 2023: $686 · 2024: $565 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,561 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,561.11 |
| Education | $169.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $926.06 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $630.67 | 2019-2025 | Breztri, Airsupra, Tezspire |
| Genzyme Corporation | $472.75 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $433.73 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $237.28 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $120.80 | 2024-2025 | Voquezna |
| Genentech USA, INC. | $114.10 | 2019-2025 | Xolair |
| Sanofi-Aventis U.S. LLC | $99.95 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.47 | 2021-2025 | Eohilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.71 | 2019-2022 | |
| Biocryst US Sales Co., LLC | $88.64 | 2021-2023 | Orladeyo |
| Grifols USA, LLC | $81.21 | 2021 | |
| Csl Behring | $65.16 | 2019 | |
| Optinose US, INC. | $50.81 | 2024 | |
| Aimmune Therapeutics, INC. | $45.08 | 2020-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $42.79 | 2025 | Neffy |
| Kaleo, INC. | $36.51 | 2019-2022 | |
| Amgen INC. | $34.00 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.25 | 2022 | |
| Abbvie INC. | $27.06 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $18.89 | 2021 | |
| Merck Sharp & Dohme LLC | $14.72 | 2023 | |
| Pfizer INC. | $11.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.